Tag: STAT+

March 9, 2026

Oregon’s Corporate Medicine Ban Faces First Major Test

March 9, 2026

Novo Nordisk & Hims & Hers End Wegovy Patent Dispute | STAT+

March 9, 2026

FDA Transparency Concerns & Biosimilar Pathway Changes | STAT News

March 9, 2026

Xenon’s Seizure Drug Shows Positive Phase 3 Trial Results | STAT

March 9, 2026

Cadence to Test Medicare’s New Pay-for-Outcomes Model for Chronic Care

March 9, 2026

FDA Criticizes Huntington’s Disease Treatment in Private Meeting with UniQure

March 9, 2026

AI & Hospital Billing: Insurers Claim $663M in Added Costs

March 9, 2026

Oregon Hospital Staffing Change Faces Legal Test | STAT+

March 8, 2026

FDA’s Vinay Prasad Steps Down: A Controversial Exit

March 6, 2026

Generic Wegovy & Ozempic: $3/Month Production Cost Could Expand Access